WO2002074239A3 - Compositions and methods for the treatment and clinical remission of psoriasis - Google Patents

Compositions and methods for the treatment and clinical remission of psoriasis Download PDF

Info

Publication number
WO2002074239A3
WO2002074239A3 PCT/US2002/006496 US0206496W WO02074239A3 WO 2002074239 A3 WO2002074239 A3 WO 2002074239A3 US 0206496 W US0206496 W US 0206496W WO 02074239 A3 WO02074239 A3 WO 02074239A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
clinical remission
psoriasis
treatment
disclosed
Prior art date
Application number
PCT/US2002/006496
Other languages
French (fr)
Other versions
WO2002074239A2 (en
Inventor
Jose Antonio O'daly
Original Assignee
Akiva Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akiva Llc filed Critical Akiva Llc
Priority to JP2002572950A priority Critical patent/JP2004535783A/en
Priority to BR0208140-7A priority patent/BR0208140A/en
Priority to CA002439916A priority patent/CA2439916A1/en
Priority to AU2002254097A priority patent/AU2002254097B2/en
Priority to MXPA03008122A priority patent/MXPA03008122A/en
Priority to EP02723312A priority patent/EP1458403A4/en
Publication of WO2002074239A2 publication Critical patent/WO2002074239A2/en
Publication of WO2002074239A3 publication Critical patent/WO2002074239A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Polypeptides comprising amino acid sequences of particulate antigens isolated from various species of Leishmania protozoa, or immunogenic variants thereof, are disclosed for the treatment and clinical remission of psoriasis. Also disclosed are nucleic acid sequences encoding such polypeptides, vectors incorporating such nucleic acid sequences, methods for genetically engineering microbial host cells to produce such polypeptides, and such recombinant microbial host cells. In another embodiment, immunotherapeutic agents incorporating the polypeptides or the nucleic acid sequences are disclosed for the treatment and clinical remission of psoriasis. In another embodiment, methods for the production of the polypeptides using recombinant microbial host cells are disclosed. Finally, methods for the treatment and clinical remission of psoriasis comprising administration of a pharmaceutical composition comprising one or more of the polypeptides or one or more of the nucleic acid sequences are disclosed. The polypeptides induced a THl cellular immune response, a positive intradermic reaction, and a blastogenic response in peripheral blood lymphocytes after clinical remission of lesions. Populations of peripheral blood lymphocytes that are altered in psoriasis patients returned to normal values in patients who received the polypeptides and experienced clinical remission of lesions after treatment.
PCT/US2002/006496 2001-03-16 2002-03-04 Compositions and methods for the treatment and clinical remission of psoriasis WO2002074239A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002572950A JP2004535783A (en) 2001-03-16 2002-03-04 Compositions and methods for treatment and clinical remission of psoriasis
BR0208140-7A BR0208140A (en) 2001-03-16 2002-03-04 Polypeptide, immunotherapeutic agent for the treatment of psoriasis, isolated nucleic acid sequence or complement, single-stranded and double-stranded vectors, isolated nucleic acid sequence or immunogenic variant thereof, methods for the production of polypeptides, and for treatment and clinical remission of psoriasis, and, microbial host cell
CA002439916A CA2439916A1 (en) 2001-03-16 2002-03-04 Compositions and methods for the treatment and clinical remission of psoriasis
AU2002254097A AU2002254097B2 (en) 2001-03-16 2002-03-04 Compositions and methods for the treatment and clinical remission of psoriasis
MXPA03008122A MXPA03008122A (en) 2001-03-16 2002-03-04 Compositions and methods for the treatment and clinical remission of psoriasis.
EP02723312A EP1458403A4 (en) 2001-03-16 2002-03-04 Compositions and methods for the treatment and clinical remission of psoriasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/809,003 US6673351B1 (en) 2001-03-16 2001-03-16 Compositions and methods for the treatment and clinical remission of psoriasis
US09/809,003 2001-03-16

Publications (2)

Publication Number Publication Date
WO2002074239A2 WO2002074239A2 (en) 2002-09-26
WO2002074239A3 true WO2002074239A3 (en) 2004-07-22

Family

ID=25200314

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/006496 WO2002074239A2 (en) 2001-03-16 2002-03-04 Compositions and methods for the treatment and clinical remission of psoriasis

Country Status (8)

Country Link
US (1) US6673351B1 (en)
EP (1) EP1458403A4 (en)
JP (1) JP2004535783A (en)
AU (1) AU2002254097B2 (en)
BR (1) BR0208140A (en)
CA (1) CA2439916A1 (en)
MX (1) MXPA03008122A (en)
WO (1) WO2002074239A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241168A1 (en) * 2001-03-16 2004-12-02 O'daly Jose A. Compositions and methods for the treatment and clinical remission of psoriasis
US20050176144A1 (en) * 2004-02-06 2005-08-11 O'daly Jose A. Culture media compositions free of fetal bovine serum
US20080159979A1 (en) * 2005-08-04 2008-07-03 Moore Emma E Treatment of wounds using il-17b
US20140356391A1 (en) * 2013-05-29 2014-12-04 Jose Antonio O'Daly Amino acid sequences for clinical remission of psoriasis and related diseases.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221843B1 (en) * 1998-04-27 2001-04-24 Incyte Genomics, Inc. Human keratins
EP1114862A2 (en) * 1999-11-17 2001-07-11 Switch Biotech Aktiengesellschaft Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0135108A3 (en) 1983-08-12 1988-07-13 Rockefeller University Nucleotide hybridization assay for protozoan parasites
FR2570947B1 (en) 1984-10-01 1987-10-02 Univ Paris Curie MONOCLONAL ANTI-LEISHMANIA ANTIBODIES, SECRET HYBRIDOMAS THEREOF, LEISHMANIA ANTIGENS RECOGNIZED BY THESE ANTIBODIES, PROCESS FOR OBTAINING AND APPLICATIONS THEREOF
EP0197062B1 (en) * 1984-10-01 1991-01-09 Institut Pasteur Anti-leishmania monoclonal antibodies, hybridomas secreting said antibodies, antigens of leishmania recognized by said antibodies, method for obtaining them and applications of said monoclonal antibodies and said antigens
US4687666A (en) 1985-02-19 1987-08-18 Ministerio De Sanidad Y Asistencia Social Instituto Venezolano De Investigationes Cientificas Vaccine for Leishmaniasis
DE3702641A1 (en) 1987-01-29 1988-08-11 Max Planck Gesellschaft PARASITOSE VACCINE
FR2612779B1 (en) 1987-03-25 1991-05-24 Univ Paris Curie BIOLOGICAL MATERIAL BASED ON LEISHMANIA AND METHOD FOR THE PRODUCTION OF ANTI-LEISHMANIAN VACCINES
FR2615103B1 (en) 1987-05-15 1990-12-07 Pasteur Institut PROCESS FOR PRODUCING LEISHMANIA FRACTIONS HAVING IMMUNOGENIC AND LYMPHOPROLIFERATIVE ACTIVITIES AND FRACTIONS OBTAINED THEREBY
IL82740A0 (en) 1987-06-01 1987-12-20 Yeda Res & Dev Assay for leishmaniasis
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
FR2619220B1 (en) 1987-08-03 1993-03-26 Pasteur Institut SPECIFIC ANTIGENS OF LEISHMANIA AND THEIR PREPARATION METHOD, ANTIGENIC PROFILES CONTAINING THESE ANTIGENS AND THEIR APPLICATION TO THE DIAGNOSIS OF VISCERAL LEISHMANIOSES.
US5202320A (en) 1989-04-06 1993-04-13 Tidwell Richard R Method for treating leishmaniasis
US5674503A (en) 1990-07-24 1997-10-07 University Of Victoria Peptides capable of eliciting an immune response to leishmaniasis and methods of using the same
FR2682107B1 (en) 1991-10-03 1995-04-21 Orstom Inst Fs Rech Scient 2-SUBSTITUTED QUINOLEINS FOR THE TREATMENT OF LEISHMANIOSIS.
US5411865A (en) 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies
DK99993D0 (en) 1993-09-03 1993-09-03 Statens Seruminstitut TREATMENT AND PROPHYLAXIS OF DISEASES CAUSED BY PARASITES OR BACTERIA
EP0716697B1 (en) 1993-09-03 2003-04-02 McGILL UNIVERSITY DIFFERENTIALLY EXPRESSED $i(LEISHMANIA) GENES AND PROTEINS
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US6013268A (en) 1994-04-22 2000-01-11 Corixa Corporation Methods for enhancement of protective immune responses
US5876735A (en) 1994-04-22 1999-03-02 Corixa Corporation Methods for enhancement of protective immune responses
WO1995029699A1 (en) 1994-04-29 1995-11-09 Curtis Powell Vaccine for, diagnostic assay for and method of treating parasitic hemoflagellate protozoa
FR2719313B1 (en) 1994-05-02 1996-07-19 Centre Nat Rech Scient Leishmania major protein, nucleic acid encoding this protein and their applications.
US6174995B1 (en) 1994-08-23 2001-01-16 Haodong Li Human chemokines, CKβ4 and CKβ10/MCP-4
US5496830A (en) 1994-09-14 1996-03-05 Johns Hopkins University Inhibition of hemoflagellates by camptothecin compounds
EP0703295A1 (en) 1994-09-26 1996-03-27 Institut Pasteur Vaccine composition comprising recombinant BCG expressing gp 63 fusion protein
US5674748A (en) 1995-03-14 1997-10-07 Thomas Jefferson University Human cyclin-dependent kinase-like proteins and methods of using the same
US5912166A (en) 1995-04-21 1999-06-15 Corixa Corporation Compounds and methods for diagnosis of leishmaniasis
US5928928A (en) 1995-06-07 1999-07-27 Universiteit Van Amsterdam Human chitinase, its recombinant production, its use for decomposing chitin, its use in therapy or prophylaxis against infection diseases
US5965142A (en) 1995-08-04 1999-10-12 Corixa Corporation Polypeptides and methods for the detection of L. tropica infection
US5658952A (en) 1995-08-29 1997-08-19 Jacobus Pharmaceutical Co., Inc. 1-[4-(4'-sulfanilyl)phenyl]urea and derivatives for the treatment of Leishmaniasis
US5834592A (en) 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6162638A (en) 1996-05-06 2000-12-19 Universite Laval Attenuated strains of leishmania and uses thereof
US5952194A (en) 1996-08-01 1999-09-14 Heska Corporation Flea nucleic acid sequences and uses thereof
WO1998035045A2 (en) * 1997-02-12 1998-08-13 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
EP0971721A1 (en) 1997-04-02 2000-01-19 Bioniche Inc. Use of bacterial cell wall extract for preventing, treating, or eliminating a protozoal or parasitic disease
US5854051A (en) 1997-09-15 1998-12-29 Heska Corporation Parasitic helminth asparaginase proteins, nucleic acid molecules, and uses thereof
US6087341A (en) 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
DE69931518T2 (en) 1998-12-23 2006-12-21 C.B.F. Leti, S.A., Tres Cantos Chimeric gene encoding the antigenic determinants of four proteins from L. Infantum

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221843B1 (en) * 1998-04-27 2001-04-24 Incyte Genomics, Inc. Human keratins
EP1114862A2 (en) * 1999-11-17 2001-07-11 Switch Biotech Aktiengesellschaft Use of polyeptides or their encoding nucleic acids for the diagnosis or treatment of skin diseases and their use in indentifying pharmacologically acitve substances

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BOETTGER V., LANE E.B.: "A monoclonal antibody epitope on keratin 8 identified using a phage peptide library", JOURNAL OF MOLECULAR BIOLOGY, vol. 235, 1994, pages 61 - 67, XP002976189 *
HENNIES H-C. ET AL.: "Keratin 9 gene mutational heterogeneity in patients with epidermolytic palmoplantar keratoderma", HUM. GENET., vol. 93, 1994, pages 649 - 654, XP008033647 *
JOHNSON L.D. ET AL.: "Structure of a gene for the human epidermal 67-kDa keratin", PROC. NATL. ACAD. SCI., vol. 82, April 1985 (1985-04-01), pages 1896 - 1900, XP001194694 *
KOBAYASHI S. ET AL.: "Keratin 9 point mutation in the pedigree of epidermolytic hereditary palmoplantar keratoderma perturbs keratin intermediate filament network formation", FEBS LETTERS, vol. 386, 1996, pages 149 - 155, XP002976188 *
REIS A. ET AL.: "Keratin 9 gene mutations in epidermolytic palmoplantar keratoderma (EPPK)", NATURE GENETICS, vol. 6, February 1994 (1994-02-01), pages 174 - 179, XP001023955 *
See also references of EP1458403A4 *
STEINERT P.M. ET AL.: "The complete cDNA and deduced amino acid sequence of a type II mouse epidermal keratin of 60,000 Da: analysis of sequence differences between type I and type II keratins", PROC. NATL. ACAD. SCI., vol. 81, September 1984 (1984-09-01), pages 5709 - 5713, XP000971065 *
TAKAHASHI K. ET AL.: "Cloning and characterization of multiple human genes and cDNAs encoding highly related type II keratin 6 isoforms", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 31, 4 August 1995 (1995-08-04), pages 18581 - 18592, XP002976186 *
TORCHARD D. ET AL.: "Epidermolytic palmoplantar keratoderma cosegregates with a keratin 9 mutation in a pedigree with breast and ovarian cancer", NATURE GENETICS, vol. 6, January 1994 (1994-01-01), pages 106 - 110, XP002976187 *

Also Published As

Publication number Publication date
EP1458403A2 (en) 2004-09-22
CA2439916A1 (en) 2002-09-26
BR0208140A (en) 2005-12-13
MXPA03008122A (en) 2004-11-12
AU2002254097B2 (en) 2006-09-14
JP2004535783A (en) 2004-12-02
WO2002074239A2 (en) 2002-09-26
EP1458403A4 (en) 2005-02-09
US6673351B1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
EP1037657B1 (en) Alpha-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
WO2002061113A3 (en) Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
WO2004016733A3 (en) Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
CA2230885A1 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
JP2004501618A5 (en)
WO2003022995A3 (en) Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
WO2003040340A3 (en) Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
WO2004022003A3 (en) Materials and methods for treatment of allergic diseases
WO2003050255A3 (en) Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer
WO2000012535A3 (en) Neisseria meningitidis polypeptide, nucleic acid sequence and uses thereof
EP0826774A3 (en) Staphylococcal Fab I enoyl-ACP reductase
EP1169441B8 (en) Pharmaceutical compositions for the treatment of heart failure
WO2002074239A3 (en) Compositions and methods for the treatment and clinical remission of psoriasis
EP2366711A3 (en) Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
HUP0400698A2 (en) Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
JP2005512518A5 (en)
JP2004513615A5 (en)
WO1998022580A3 (en) Bovine lactation associated immunotropic protein (cd14), encoding gene and application in b cell activation
WO2002081519A3 (en) Ifn-thy fusion protein,dna coding therefore,its preparation and application
WO2005058944A3 (en) Immunogenic peptides fragments of xage-1
WO2002016578A3 (en) Secreted proteins and methods of using same
Chen et al. Thymosins and other thymic hormones
Moloney et al. Immunotolerance to ox insulin induced in the adult guinea pig.
EP0846766A3 (en) IgA Fc binding protein from Streptococcus pneumoniae
WO2002078607A3 (en) Mucin peptide with immunoenhancing properties

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2439916

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002723312

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008122

Country of ref document: MX

Ref document number: 2002254097

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002572950

Country of ref document: JP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002723312

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: PI0208140

Country of ref document: BR